Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ex-HHS official joins VaxGen board

Executive Summary

Eve Slater joins VaxGen board of directors. Slater served as assistant secretary for health and chief policy advisor to former HHS Secretary Tommy Thompson. Before joining HHS, she was Merck's VP-external policy & public affairs. Slater also serves on the board of data management solutions firm Phase Forward and Vertex Pharmaceuticals (1"The Pink Sheet" June 27, 2005, In Brief)...

You may also be interested in...



Theravance board adds Slater

Former HHS Assistant Secretary for Health Eve Slater has joined Theravance's board of directors, the firm announced Dec. 12. Before joining HHS, Slater was Merck VP-external policy & public affairs. Slater rejoins former Merck CEO and current Theravance Chairman Roy Vagelos on the board. Slater serves on the boards of a number of other firms, including Vertex and VaxGen (1"The Pink Sheet" July 18, 2005, In Brief)...

Phase Forward adds former HHS official

Eve Slater will join board of directors at Phase Forward, a provider of data management solutions for clinical trials and drug safety, on June 30. Slater was assistant secretary for health and chief policy advisor to former HHS Secretary Thompson. Before joining HHS, Slater was VP-external policy & public affairs at Merck. In addition, Covington & Burling partner and former FDA General Counsel Peter Barton Hutt is resigning his position on the Phase Forward board...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046079

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel